Disease relevance of ethyl phenylacetyl-Pro-Gly

• GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons [1].
• The results suggest that the neuroprotective effect of GVS-111 against oxidative damage and its potential nootropic activity may present a valuable therapeutic combination for the treatment of mental retardation and chronic neurodegenerative disorders [1].
• Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress [2].

Psychiatry related information on ethyl phenylacetyl-Pro-Gly

• Effect of noopept and afobazole on the development of neurosis of learned helplessness in rats [3].

High impact information on ethyl phenylacetyl-Pro-Gly

• Taurine and the mitochondrial enhancer l-carnitine, but not the antioxidants (ascorbate, carnosine, and the novel compound GVS-111) or the osmolyte betaine prevented this impairment [4].
• Cyclopropyl glycine and proline-containing preparation noopept evoke two types of membrane potential responses in synaptoneurosomes [5].
• Proline, cyclo(Pro-Gly), and acyl-prolyl-containing dipeptide GVS-111 decreased synaptoneurosome membrane potential in a Ca2+-free medium [5].
• Impairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of Noopept [6].
• The acyl-prolyl-containing dipeptide Noopept facilitated retention and retrieval of a conditioned passive avoidance response, normalized learning capacity in animals with ischemic damage to the cerebral cortex, and promoted finish training in rats with hereditary learning deficit [6].

Biological context of ethyl phenylacetyl-Pro-Gly

• Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC [7].

Associations of ethyl phenylacetyl-Pro-Gly with other chemical compounds

• Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration [8].
• The metabolism of a new piracetam analogue, the dipeptide cognitive enhancer N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111) was studied in vivo [9].

Gene context of ethyl phenylacetyl-Pro-Gly

• GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions [9].

References